June 15, 1963

Council on Drugs

JAMA. 1963;184(11):887. doi:10.1001/jama.1963.03700240079013

New Drugs and Developments in Therapeutics

Pargyline Hydrochloride (Eutonyl)

PARGYLINE HYDROCHLORIDE is a new nonhydrazine monoamine oxidase inhibitor which appears to be an effective hypotensive agent in most of the patients in whom the drug has been used. However, the hypotension produced is primarily orthostatic, and a majority of the clinical studies have failed to demonstrate any significant lowering of blood pressure in hypertensive patients when they are in the recumbent position. The full therapeutic effect develops slowly and is maintained for some time after the drug is discontinued. The mechanism by which pargyline produces its antihypertensive effect is not known.

The claim that pargyline induces a sense of wellbeing in many patients is not wholly substantiated by the data presently available. Further observation and clinical study are under way to determine its possible value as an antidepressant.

Adverse Reactions.  —Postural hypotension, as evidenced by weakness, fainting, and dizziness, can

First Page Preview View Large
First page PDF preview
First page PDF preview